Use of Cyclophilin inhibitors in the treatment of hepatitis C virus infectionClaim 1: alisporivir for use in the treatment of a patient infected with the hepatitis C virus, genotype 1, in combination with the standard of Care Treatment.Wherein: (i) the patient is a patient or a patient Relapse did not respond to previous treatment； and (ii) alisporivir administered during an initial phase in an amount of about 600 mg twice per day； followed by the Administration of alisporivir during a Second To phase in a quantity of about 600 to about 1000 mg, once per day.Claim 8: the use of alisporivir in the preparation of a Medicament for the treatment of a patient infected with the hepatitis C virus, genotype 1, wherein: (i) the patient is a patient or a patient Relapse did not respond to previous treatment； and (ii) alispor Iving administered during an initial phase in an amount of about 600 mg.Two times per day for 7 days, followed by administration of alisporivir during a Second Phase, in an amount of about 600 to 800 mg once a day for up to 23 weeks or 71, 47； and where alisporivir is administered in combination with standards of Care Treatment during the initial phase and the second phase.Claim 11: a Pharmaceutical composition comprising alisporivir for the use according to claim 1.Uso de inhibidores de ciclofilina en el tratamiento de la infección del virus de la hepatitis C.Reivindicación 1: Alisporivir para el uso en el tratamiento de un paciente infectado con el virus de la hepatitis C, genotipo 1, en combinación con las normas asistenciales de tratamiento, caracterizado porque: (i) el paciente es un paciente de recaída o un paciente que no responde al tratamiento previo； y (ii) alisporivir se administra durante una fase inicial en una cantidad de alrededor de 600 mg, dos veces por día； seguido de la administración de alisporivir durante una segunda fase en una cantidad de alrededor de 600 a alrededor de 1000 mg, una vez por día. Reivindicación 8: El uso de alisporiv
